| Describe the mechanism of action for talimogne laherparepvec (T-VEC) |
|
|
|
|
|
| Describe how checkpoint inhibitors, both CTLA-4 and PD-L1, alter the body’s immune response to melanoma cells |
|
|
|
|
|
| Describe potential toxicities associated with checkpoint inhibitors, including etiology of these toxicities and management and/or prophylaxis |
|
|
|
|
|
| Explain how checkpoint inhibitors differ from other available treatment options for metastatic melanoma, including kinase inhibitors and cytotoxic chemotherapy |
|
|
|
|
|
| Discuss the role of the advanced practitioner as part of the collaborative practice team in caring for patients on immunotherapy treatments |
|
|
|
|
|
